Comparison of two different coagulation algorithms on the use of allogenic blood products and coagulation factors in severely injured trauma patients: a retrospective, multicentre, observational study by Kaserer, Alexander et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Comparison of two different coagulation algorithms on the use of allogenic
blood products and coagulation factors in severely injured trauma patients:
a retrospective, multicentre, observational study
Kaserer, Alexander; Casutt, Mattias; Sprengel, Kai; Seifert, Burkhardt; Spahn, Donat R; Stein, Philipp
Abstract: BACKGROUND:At the University Hospital Zurich (USZ) and the Cantonal Hospital of
Lucerne (LUKS) an individualized goal-directed coagulation and transfusion algorithm was introduced
and implemented before 2012 (Coagulation algorithm of the USZ: USZ-Alg; of the LUKS: LUKS-Alg).
Main differences between both algorithms are: 1) A target haematocrit-range of 0.21-0.24 (USZ-Alg) vs.
a lower haematocrit limit only (LUKS-Alg). 2) Blind coagulation-package in selected cases (LUKS-Alg
only). 3) Factor XIII substitution is considered earlier according to the USZ-Alg. The Aim of this study
was to analyse the impact of two different coagulation algorithms on the administration of allogeneic
blood products, coagulation factors, the frequency of point of care measurements and haemoglobin level
during resuscitation in trauma patients. METHODS:This retrospective, multicentre, observational study
included all adult trauma patients with an injury severity score (ISS) ￿ 16 primarily admitted to the
USZ or the LUKS in the period of 2012 to 2014. Referred patients and patients with missing/incom-
plete records of the initial treatment at the emergency department (ED) were excluded. Two propensity
score matched groups were created using a non-parsimonious logistic regression to account for potential
differences in patient and trauma epidemiology. RESULTS:A total of 632 patients meeting the inclusion
criteria were admitted to the two hospitals: 428 to the USZ and 204 to the LUKS. Two Propensity score
matched groups (n = 172 per group) were created. Treatment with USZ-Alg compared with LUKS-Alg
resulted in a lower number of patients receiving RBC transfusion (11.6% vs. 29.7%, OR 3.2, 95% CI
1.8-5.7, p < 0.001) and lower amount of RBC transfusion (0.5 SD 1.9 vs. 1.5 SD 3.9, p < 0.001). The
different treatment algorithms resulted in lower mean haemoglobin levels in the USZ during resuscitation
(8.0 SD 1.7 vs. 9.4 SD 1.8 g/dl, p < 0.001) and at admission to the ICU (8.3 SD 1.2 vs. 10.6 SD 1.9
g/dl, p < 0.001. Blood gas analyses to monitor treatment and haematocrit were made more frequently in
the USZ (1.4 SD 0.8 vs. 1.0 SD 0.7 measurements per hour, p = 0.004). CONCLUSION:A goal-directed
coagulation algorithm including a target haematocrit-range including frequent and repeated haematocrit
measurement may lead to less transfusion of RBC compared to only a lower haematocrit limit, when
treating severely traumatized patients. KEYWORDS:Coagulation algorithm; Coagulation management;
Point of care measurements; Transfusion; Trauma
DOI: https://doi.org/10.1186/s13049-017-0463-0
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-145906
Published Version
 
 
Originally published at:
Kaserer, Alexander; Casutt, Mattias; Sprengel, Kai; Seifert, Burkhardt; Spahn, Donat R; Stein, Philipp
(2018). Comparison of two different coagulation algorithms on the use of allogenic blood products and
coagulation factors in severely injured trauma patients: a retrospective, multicentre, observational study.
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine:26:4.
DOI: https://doi.org/10.1186/s13049-017-0463-0
2
ORIGINAL RESEARCH Open Access
Comparison of two different coagulation
algorithms on the use of allogenic blood
products and coagulation factors in
severely injured trauma patients: a
retrospective, multicentre, observational
study
Alexander Kaserer1* , Mattias Casutt2, Kai Sprengel3, Burkhardt Seifert4, Donat R. Spahn1 and Philipp Stein1
Abstract
Background: At the University Hospital Zurich (USZ) and the Cantonal Hospital of Lucerne (LUKS) an individualized
goal-directed coagulation and transfusion algorithm was introduced and implemented before 2012 (Coagulation
algorithm of the USZ: USZ-Alg; of the LUKS: LUKS-Alg). Main differences between both algorithms are: 1) A target
haematocrit-range of 0.21–0.24 (USZ-Alg) vs. a lower haematocrit limit only (LUKS-Alg). 2) Blind coagulation-package
in selected cases (LUKS-Alg only). 3) Factor XIII substitution is considered earlier according to the USZ-Alg.
The Aim of this study was to analyse the impact of two different coagulation algorithms on the administration of
allogeneic blood products, coagulation factors, the frequency of point of care measurements and haemoglobin
level during resuscitation in trauma patients.
Methods: This retrospective, multicentre, observational study included all adult trauma patients with an injury
severity score (ISS) ≥ 16 primarily admitted to the USZ or the LUKS in the period of 2012 to 2014. Referred patients and
patients with missing/incomplete records of the initial treatment at the emergency department (ED) were excluded.
Two propensity score matched groups were created using a non-parsimonious logistic regression to account for
potential differences in patient and trauma epidemiology.
Results: A total of 632 patients meeting the inclusion criteria were admitted to the two hospitals: 428 to the USZ
and 204 to the LUKS. Two Propensity score matched groups (n = 172 per group) were created. Treatment with
USZ-Alg compared with LUKS-Alg resulted in a lower number of patients receiving RBC transfusion (11.6% vs. 29.7%,
OR 3.2, 95% CI 1.8–5.7, p < 0.001) and lower amount of RBC transfusion (0.5 SD 1.9 vs. 1.5 SD 3.9, p < 0.001). The
different treatment algorithms resulted in lower mean haemoglobin levels in the USZ during resuscitation (8.0 SD
1.7 vs. 9.4 SD 1.8 g/dl, p < 0.001) and at admission to the ICU (8.3 SD 1.2 vs. 10.6 SD 1.9 g/dl, p < 0.001. Blood gas
analyses to monitor treatment and haematocrit were made more frequently in the USZ (1.4 SD 0.8 vs. 1.0 SD 0.7
measurements per hour, p = 0.004).
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Conclusion: A goal-directed coagulation algorithm including a target haematocrit-range including frequent and
repeated haematocrit measurement may lead to less transfusion of RBC compared to only a lower haematocrit
limit, when treating severely traumatized patients.
Keywords: Coagulation algorithm, Coagulation management, Point of care measurements, Transfusion, Trauma
Background
Individualized goal-directed point-of-care and factor
concentrate based coagulation and transfusion algo-
rithms to treat massively bleeding patients following
severe trauma have been published [1–4]. Such algo-
rithms require adequate, fast and goal-directed replace-
ment of plasma components and coagulation factors to
tackle trauma induced coagulopathy and its conse-
quences, particularly mortality [5, 6]. It could already
be shown that the implementation of transfusion and
coagulation algorithms leads to an improved outcome
with a significant reduction of mortality, massive trans-
fusion and the use of allogeneic blood products [1, 3, 7].
Coagulation management according to individualized
goal-directed coagulation and transfusion algorithms is
one of the key elements in the European Trauma Treat-
ment Guidelines [8].
In 2008, the University Hospital of Zurich (USZ),
Switzerland, implemented an algorithm for goal directed
transfusion and coagulation management based on the
pathophysiology of a developing coagulopathy in massively
bleeding patients [9]. The algorithm was subsequently re-
vised and then fully implemented in 2012 [1, 10, 11]. A
similar algorithm was implemented in the Cantonal Hos-
pital of Lucerne (LUKS), Switzerland, in 2011.
Although both algorithm base on the same principles
and are largely comparable, some differences exist.
These differences may have significant influence on the
administration of allogeneic blood products and coagu-
lation factors. To the best of our knowledge no study
has been conducted and published comparing two goal-
directed, point of care and factor based coagulation
algorithms. The aim of this study was to analyse the
impact of the differences between two distinct transfu-
sion and coagulation algorithms on the administration
of allogeneic blood products, coagulation factors, the
frequency of point of care measurements and haemo-
globin levels during resuscitation.
Methods
This study was approved by the local ethics committee
(Kantonale Ethikkommission Zürich, Switzerland, KEK
ZH 2015–0309) and adheres to the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) recommendations for cohort studies [12].
Study design and participants
This retrospective, multicentre, observational study in-
cludes all adult trauma patients (≥ 16 years) with an In-
jury Severity Score (ISS) ≥ 16 primarily admitted to the
USZ or the LUKS between January 1, 2012 and
December 31, 2014.
Exclusion criteria were secondary transfer to the USZ
or LUKS, Age < 16 years and missing/incomplete re-
cords of the initial treatment at the emergency depart-
ment (Fig. 1).
Setting
The USZ and LUKS are two of twelve level 1 trauma
centres in Switzerland. All severely injured patients are
transferred by ambulance or helicopter to one of these
level 1 trauma centres. A standardized clinical approach
is provided in the emergency department (ED) of the
USZ and LUKS consisting of a primary survey and fur-
ther treatment according to ATLS® or ETC®. The trauma
staff at the ED contains at least one senior and one jun-
ior anaesthetist one senior and one junior trauma sur-
geon. An initial whole-body CT scan is performed in all
Fig. 1 Flowchart of patient selection according to defined inclusion
and exclusion criteria. LUKS: Cantonal Hospital Lucerne; USZ: University
Hospital Zurich; ISS: Injury severity score
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major trauma patients as soon as possible to evaluate
their relevant injuries and to determine further treat-
ment [13].
Transfusion and coagulation algorithm
At the USZ in 2008 an individualized goal-directed trans-
fusion and coagulation algorithm was introduced, revised
and fully implemented until 2012 (USZ-Alg) [9–11]. At
the LUKS, a similar coagulation algorithm was introduced
and implemented during 2011 (LUKS-Alg). Both algo-
rithm guide the transfusion and coagulation management
for all massively bleeding trauma patients.
Basics of both algorithm
On admission to the ED, blood samples to determine
haemoglobin level, platelet count, fibrinogen level, factor
V and XIII activity, international normalized ratio (INR),
aPTT, blood gas analysis (ABGA) and ROTEM® (Rota-
tional thromboelastometry, TEM International, Munich,
Germany) analysis are taken. Haematology assays and
factor activity measurement are available 24 h a day,
within 30 min. ROTEM® measurements include EXTEM
(tissue factor activated extrinsic pathway), INTEM (el-
lagic acid activated intrinsic pathway), FIBTEM (contain-
ing platelet inhibitor cytochalasin D, evaluating the
contribution of fibrinogen to clot formation) and
APTEM (containing aprotinin to inhibit plasmin to
evaluate fibrinolysis). The first step is to screen patient’s
medical history and medication to identify factors affec-
ting coagulation (antiplatelet drugs, heparin, oral anti-
coagulants or history of immune reactions altering
coagulation). General target values include normother-
mia, normocalcemia, normal acid-base status, adequate
haematocrit, permissive hypotension (mean arterial pres-
sure 55–60 mmHg). Fluid resuscitation should primarily
be performed with balanced crystalloid solutions. If col-
loids are considered to be useful, only gelatin adminis-
tration is recommended in both algorithms. Tranexamic
acid (TXA), fibrinogen concentrate, 4 factor prothrom-
bin complex concentrate (PCC), factor XIII and allogen-
eic blood products are administered according to
laboratory, ABGA and ROTEM® findings. If target values
are reached, diffuse bleeding continues and a DIC is not
likely, recombinant factor VIIa may be evaluated.
Main differences between both algorithm
 For the RBC transfusion management, a target
haematocrit-range of 0.21–0.24 is specified in
USZ-Alg, whereas in LUKS-Alg only a lower
haematocrit limit of 0.21 is defined.
 LUKS-Alg contains the option for selected
Trauma patients (age < 50 years, no fatal injury,
temperature > 35 °C and diffuse bleeding) to
administer the following transfusion - and
coagulation package blindly and not goal-directed:
2 g Tranexamic acid, 4 g Fibrinogen, 1′000 U
Prothrombin complex concentrate, 4 RBCs
(blood group 0 negative) and 1250 U factor XIII.
 In the LUKS-Alg, Factor XIII 1250 U (15 U/kg) is
considered if FIBTEM maximum clot firmness stays
≤ 7 mm despite fibrinogen administration, or factor
XIII activity is < 60%. According to the USZ-Alg
Factor XIII may be administering blindly after 6 g
of fibrinogen or at factor XIII activity < 60% to
improve clot stabilization.
The LUKS-Alg is depicted in detail in the supplemental
material (Additional file 1). The USZ-Alg is depicted in
detail in the publication of Theusinger et al. [10].
Variables and data collection
Patient demographics, laboratory values at admission
(samples collected within the first minutes after admis-
sion to the hospital) and injury epidemiology were ex-
tracted from the internal database which is collected and
entered by professional medical coders responsible for
the data acquisition to the TraumaRegister DGU(R) of
the German Trauma Society and copied to a designated
spreadsheet (Microsoft® Office Excel 2010, Microsoft®
Corporation, Redmond, USA). Additionally, the following
variables concerning initial resuscitation in the emergency
department (hospital admission to ICU admission) were
extracted from the anaesthesia records: use of resusci-
tation fluids, factor concentrates (PCC, factor XIII, re-
combinant factor VIIa), TXA, vasopressor use (yes/no),
duration of treatment and the use of allogeneic blood
products such as RBC, FFP and PLT. Multiple cross
checks have been performed to ensure high data quality.
The median proportion of missing values was 1.4%, IQR 0
to 4.7%.
Endpoints and outcome variables
The primary endpoints were the comparison between
centres / algorithms in the use of allogenic blood products
and coagulation factors. Secondary endpoints were the
frequency of point of care measurements and haemoglo-
bin level during resuscitation and at admission ICU.
Statistical analyses
Numerical data reported as mean and standard deviation
(SD) or median [Q1;Q3] in the case of skew data distri-
bution and ordinal data (GCS). Categorical data shown
in absolute numbers (n) and percent (%). For the primary
analysis, two propensity score matched groups (n = 172
per group) were computed using a non-parsimonious
logistic regression. Skew data was logarithmically trans-
formed (time in the ED, time prehospital, platelet count,
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lactate). Propensity score matching was performed on
the logit scale with a caliper of 0.2 standard deviations
of the logit of the propensity score. Missing values were
replaced by multiple regression imputation for the re-
spective analysis (dataset was generated using 10 itera-
tions of automatic (linear or logistic) regressions
depending on the type of the variable). The model fit
was assessed using the Hosmer–Lemeshow test. The
model was well calibrated (chi-square with 8 degrees of
freedom = 11.4, p = 0.16). Standardized difference was
calculated for the (partially logarithmically transformed)
explanatory variables (Table 1) to assess the balance on
base line characteristics after propensity score matching.
Odds ratios (OR) and 95% CI were calculated using lo-
gistic regression. The Mann-Whitney test was used to
compare continuous data between the groups. Statistical
significance was set as a two-tailed p-value ≤ 0.05. All sta-
tistical analyses were performed by IBM SPSS Statistics 22
(Armonk, NY: IBM Corp).
Results
A total of 632 patients meeting the inclusion criteria
were admitted to the two hospitals: 428 patients were
admitted to the USZ and 204 to the LUKS (Fig. 1). Two
Propensity score matched groups (n = 172 per group)
were created with the explanatory variables in Table 1.
The absolute standardized difference after matching was
≤0.13 for all explanatory variables, stating an acceptable
balance between the matched groups (Table 1).
Usage of blood products, coagulations factors and
resuscitation fluids
Treatment with USZ-Alg compared with LUKS-Alg re-
sulted in a lower number of patients receiving RBC
transfusion (11.6% vs. 29.7%, OR 3.2, 95 CI 1.8–5.7, p <
0.001, Table 2) and a lower amount of RBC transfusion
(0.5 SD 1.9 vs. 1.5 SD 3.9, p < 0.001, Table 3). Concern-
ing FFP and PLT transfusions, the number of patients
transfused and the amount of transfused units did not
differ between the algorithms. In patients treated accord-
ing to the USZ-Alg, mean haemoglobin level in trans-
fused patients was lower during resuscitation (8.0 SD 1.7
vs. 9.4 SD 1.8 g/dl, p < 0.001) and at ICU admission (8.3
SD 1.2 vs. 10.6 SD 1.9 g/dl, p < 0.001, Figs. 2 and 3).
If treated according to the USZ-Alg, significantly more
patients received factor XIII, but less patients received
PCC and fibrinogen concentrate (Table 2). The mean
overall dose was higher for factor XIII and lower for
PCC and fibrinogen if USZ-Alg was applied (Table 3).
None of the patients received recombinant factor VIIa.
Table 1 Overview of patient characteristics, mechanisms of injury, management and first laboratory values determined at
admission in the propensity score matched groups comparing two 1 trauma centres (LUKS: Cantonal Hospital Lucerne, USZ:
University Hospital Zurich)
USZ (n = 172) LUKS (n = 172) Standardized difference
Age (years) 53.6 (21.8) 51.1 (19.7) 0.09
Sex (male) 119 (69%) 121 (70%) 0.03
Heart rate (bpm) on admission 90 (23) (n = 169) 91 (21) (n = 167) 0.04
Systolic blood pressure (mmHg) on admission 131 (27) (n = 171) 132 (31) (n = 168) 0.04
Penetrating trauma 8 (5%) 6 (4%) (n = 169) 0.06
GCS on scene 13 [6;15] (n = 167) 13 [6;15] (n = 169) 0.09
ISS 27.8 (14.5) 27.9 (11.5) 0.01
Time (min.) prehospital 65 [55;84] 70 [55;90] (n = 143) 0.01#
Time (min.) ED 145 [100;255] 170 [105;309] (n = 143) 0.11#
Prehospital intubation 48 (28%) 56 (33%) 0.10
Vasopressor use (in the ED) 90 (52%) 93 (54%) 0.03
First laboratory values determined after admission to the ED
Haemoglobin (g/dl) 12.1 (2.1) (n = 166) 12.1 (2.3) (n = 169) 0.00
Platelet count (G/l) 186 [152;225] (n = 167) 197 [164;227] (n = 164) 0.10#
Base Excess (mmol/l) −3.5 (4.9) (n = 165) −2.8 (5.5) (n = 165) 0.12
Lactate (mmol/l) 1.7 [1.1;2.6] (n = 166) 1.7 [1.0;3.0] (n = 148) 0.13#
Quick’s value (%) 71 (22) (n = 167) 73 (19) (n = 166) 0.09
Fibrinogen (g/l) 2.3 (1.0) (n = 160) 2.3 (0.8) (n = 162) 0.07
Data reported as frequency (n) with percentage (%), mean (SD) or median [Q1;Q3]. Standardized difference for the explanatory variables = absolute difference in
means or proportions divided by pooled standard deviation. #: standardized difference computed for logarithmically transformed variable. Standardized difference
is ≤ 0.13 for all explanatory variables, stating an acceptable balance between the matched groups
BPM beats per minute, ED emergency department, GCS glasgow coma scale, ISS injury severity score
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Patients treated according to the USZ algorithm received
significantly lower volumes of crystalloids (Table 3), less
frequently and lower volumes of hydroxyethyl starch but
more frequently and higher volumes of gelatin (Tables 2
and 3).
Point of care measurements during resuscitation
In patients receiving RBC, more blood gas analyses were
made at the USZ (1.4 SD 0.8 vs. 1.0 SD 0.7 measure-
ments per hour, p = 0.004). No significant differences in
the amount of ROTEM® analyses could be observed
between both algorithms (0.5 SD 0.4 vs. 0.5 SD 0.4 mea-
surements per hour, p = 0.83).
Discussion
The treatment of severely injured patients with individu-
alized goal-directed factor based coagulation and trans-
fusion algorithms is becoming more and more common
nowadays and many hospitals already implemented such
algorithms. Although common practice, to the best of
our knowledge this is the first study investigating the
impact of differences in coagulation algorithms on the
administration of allogeneic blood products and coagula-
tion factors, point of care measurements and haemoglo-
bin level during resuscitation and at admission ICU.
Our main findings were 1) a target haematocrit-range
may lead to less transfusion of RBC compared to a lower
haematocrit limit only, 2) especially in patients requiring
allogenic blood products frequently repeated haemoglo-
bin measurement may be crucial to monitor transfusion
management.
Following to the USZ-Alg, frequency and amount of
RBC transfusions were significantly lower. In severely in-
jured trauma patients RBC transfusion is only recom-
mended according to evidence based low transfusion
triggers [14–17]. As RBC do not contain any coagulation
factors RBC transfusions lead to dilution of coagulation
factors, which may worsen the bleeding [9]. Therefore,
in the USZ-Alg a haematocrit-range as RBC transfusion
target is established, avoiding excessive RBC transfusion.
This may additionally be reflected by the higher amount
of ABGA performed per hour at the USZ to focus on
the haematocrit-range in transfused patients compared
to the LUKS, where the haemoglobin level is considered
to be kept upper a lower haematocrit limit only.
In Switzerland, prehospital tranexamic acid adminis-
tration was initiated after the CRASH-2 trial was pub-
lished in 2011 [18]. Therefore, the use of tranexamic
acid may be underestimated for both centres, because
prehospital administration of tranexamic acid was not
analysed. No additional tranexamic acid was given and
documented in the ED, if prehospital TXA was already
applied. Early empirical administration of tranexamic
acid is recommended by the European Trauma Treat-
ment Guidelines to bleeding trauma patients or patients
at risk of significant haemorrhage [8].
A difference in fibrinogen concentrate administration
was observed, which may be due to goal-directed use ac-
cording to the USZ-Alg, compared to empirical (par-
tially) use of fibrinogen concentrate according to the
LUKS-Alg. As fibrinogen concentrate substitution re-
duces the need for FFP and RBC transfusion in trauma
patients [19], rapid assessment and correction of the ini-
tial fibrinogen level is recommended by both algorithms.
Table 2 Differences in the number of patients receiving
allogeneic blood products, coagulation factors and resuscitation
fluids (independent of amount) between the propensity score
matched groups (LUKS: Cantonal Hospital Lucerne, USZ:
University Hospital Zurich)
USZ (n = 172) LUKS (n = 172) OR (95% CI) p-value
RBC 20 (11.6%) 51 (29.7%) 3.2 (1.8–5.7) < 0.001
FFP 4 (2.3%) 9 (5.2%) 2.3 (0.7–7.7) 0.16
PLT 10 (5.8%) 6 (3.5%) 0.6 (0.2–1.6) 0.31
TXA 76 (44.2%) 66 (28.6%) 0.8 (0.5–1.2) 0.29
Fibrinogen 42 (24.4%) 59 (34.3%) 1.6 (1.0–2.6) 0.04
PCC 17 (9.9%) 41 (23.8%) 2.9 (1.5–5.3) 0.001
Factor XIII 15 (8.7%) 6 (3.5%) 0.4 (0.1–1.0) 0.04
Starch 5 (2.9%) 37 (21.5%) 9.2 (3.5–23.9) < 0.001
Gelatin 47 (27.3%) 27 (15.7%) 0.5 (0.3–0.8) 0.009
Data reported as frequency (n) with percentage (%). Odds ratio (OR) with 95%
confidence intervals (CI) and p-values were calculated using logistic regression.
Level of significance 0.05
FFP fresh frozen plasma, FXIII coagulation factor XIII, PCC 4 factor prothrombin
complex concentrate, PLT platelet concentrate, RBC red blood cell concentrate,
TXA tranexamic acid
Table 3 Differences in the amount/quantity of administered
allogeneic blood products, coagulation factors and resuscitation
fluids between the propensity score matched groups (LUKS:
Cantonal Hospital Lucerne, USZ: University Hospital Zurich)
USZ (n = 172) LUKS (n = 172) p-value
RBC (U) 0.5 (1.9) 1.5 (3.9) < 0.001
FFP (U) 0.1 (0.6) 0.4 (2.2) 0.15
PLT (U) 0.1 (0.3) 0.1 (0.4) 0.32
FFP:RBC (ratio) 0.1 (0.3) 0.1 (0.3) 0.91
Fibrinogen (g) 1.1 (2.6) 1.5 (3.0) 0.05
PCC (IU) 124 (408) 454 (1011) < 0.001
Factor XIII (IU) 116 (388) 51 (282) 0.04
Crystalloid (ml) 2130 (2642) 3944 (4064) < 0.001
Starch (ml) 13 (94) 146 (319) < 0.001
Gelatin (ml) 347 (722) 142 (392) 0.004
Data reported as mean (SD). The p-value (Mann-Whitney test) was calculated
between the groups. Level of significance 0.05
FFP fresh frozen plasma, FXIII coagulation factor XIII, PCC 4 factor prothrombin
complex concentrate, PLT platelet concentrate, RBC red blood cell concentrate
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Fig. 2 Mean haemoglobin during resuscitation at the ED. In Patients from the propensity score matched groups requiring at least 1 RBC, mean
haemoglobin level during resuscitation at the emergency department was significantly different between both trauma centres: p < 0.001. RBC: red
blood cell concentrate; ED: emergency department; USZ-Alg: coagulation and transfusion algorithm of the University Hospital Zurich; LUKS-Alg:
coagulation and transfusion algorithm of the Cantonal Hospital Lucerne
p<0.001
Fig. 3 First haemoglobin on ICU. In patients from the propensity score matched groups requiring at least 1 RBC, first haemoglobin level on admission to
the ICU was significantly different between both trauma centres: p< 0.001. ICU: intensive care unit; RBC: red blood cell concentrate; USZ-Alg: coagulation
and transfusion algorithm of the University Hospital Zurich; LUKS-Alg: coagulation and transfusion algorithm of the Cantonal Hospital Lucerne
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At the LUKS patients received PCC more frequently
and at a higher dosage. Although PCC is part of the
“blind package” for selected trauma cases according to
LUKS-Alg, the European Trauma Treatment Guidelines
recommend PCC administration only to bleeding pa-
tients with documented evidence of delayed coagulation
initiation (goal-directed approach) and to trauma pa-
tients who are anticoagulated with vitamin K antagonists
[8]. Treating patients blindly with PCC is therefore not
recommended and may explain the observed difference
for PCC between both centres.
The majority of trauma patients in both centres is no
longer exposed to FFP transfusions. As FFP was the only
source for coagulation factor XIII, this factor may reach
critically low values in bleeding patients with progressive
haemodilution. Therefore, measurement and early ad-
ministration of factor XIII is recommended. It was
shown that factor XIII stabilizes the fibrin clot in vitro
[20] and reduces postoperative bleeding in cardiac sur-
gery [21]. More coagulation factor XIII was administered
at the USZ as it is earlier recommended according to
the USZ-Alg.
In both trauma centres, crystalloid solutions are
used primarily for fluid resuscitation. Patients at the
USZ received a more restrictive volume resuscitation.
Restrictive fluid resuscitation is recommended to avoid
dilution of coagulation factors, which impairs coagulation
additionally until the bleeding is surgically controlled [8].
On the other hand the survival > = 72 h in severely injured
patient is associated with a higher amount of especially
saline solutions indicating that some patients may
benefit from a more generous fluid resuscitation [22].
The overall numbers of patients that received colloids
were comparable between the LUKS and the USZ.
Whereas at the USZ used predominantly gelatin, the
LUKS used gelatin and hydroxyethyl starch equally
frequently throughout the study period, despite the fact
both algorithms recommend the use of gelatin. This
might be explained by the fact, that the negative, non-
reversible effect of starch on coagulation was postulated
during the observed study period. It was shown that
colloid solutions are affecting coagulation as well as
they are an independent predictor of SIRS and Sepsis in
severely injured patients [23–25]. Thereby especially
starch worsens blood coagulation by impairing fibrin
polymerization and platelet function [20, 26]. In con-
trast to gelatin, this negative impact on coagulation of
hydroxyethyl starch is not reversible by adding coagula-
tion factor concentrates [23, 26].
Individualized goal-directed factor concentrate-based
algorithms are based on point of care measurements
and routine laboratory measurements. Point of care
measurements, including viscoelastic testing of the
developing clot (e.g. ROTEM®) and ABGA, allow rapid
and tailored coagulation and transfusion treatment [3, 27].
The FIBTEM test in viscoelastic testing with ROTEM®
allows to identify low functional fibrinogen levels
within 5–10 min [27]. Low levels are shown to be pre-
dictive for massive transfusion in trauma patients [19].
A ROTEM®-guided haemostatic therapy with fibrinogen
concentrate and PCC led to a reduction in the adminis-
tration of allogeneic blood products in trauma patients
[3, 4, 28, 29]. Moreover, a TEG®-guided protocol was
shown to be superior to a massive transfusion protocol
with a fixed ratio strategy in patients with penetrating
trauma [2]. It is therefore crucial that point of care
measurements are frequently repeated to guide and
monitor the coagulation and transfusion management,
especially after administering coagulation factors and
allogeneic blood products.
Limitations
Our study has several limitations hat may have inter-
fered with our results. Data analyses were performed
retrospectively. However, data quality is high, as all
the emergency department data have been collected
independently and cross-checked. Moreover, docu-
mentation was performed according to the Good
Clinical Practice guidelines. Both trauma centres have
a standardized approach for the initial treatment of
severely injured patients based on to leading trauma
guidelines, such as ATLS® or ETC®. Nevertheless,
apart from the differences in the coagulation algo-
rithms, also other differences in the treatment of
trauma patients may not be accounted for despite the
fact that after matching, demographic and trauma
epidemiology including admission laboratory values
did not differ between the groups. From this study
design, therefore only associations but no causal rela-
tionships may be derived. Treatment differences may
not be limited to the investigated algorithms only, but
also to undetermined differences between the study
centres. Conducting a prospective multicentre study
to investigate 2 coagulation algorithms in parallel
would be difficult to perform, as for example blinding
is not possible. Therefore, comparing two coagulation
algorithms retrospectively and showing differences in
the transfusion of allogeneic blood products may be
considered a pragmatic approach.
Conclusion
A goal-directed coagulation algorithm including a target
haematocrit-range including frequent and repeated
haematocrit measurement may lead to less transfusion
of RBC compared to only a lower haematocrit limit,
when treating severely traumatized patients.
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